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Summary Diffuse panbronchiolitis (DPB) can now be cured with long-term erythro-
mycin treatment. Our group conducted a prospective open trial of long-term
treatment with a macrolide antibiotic, clarithromycin. We studied ten patients who
were treated for 4 years with oral clarithromycin (200mg once a day). Pulmonary
function test, blood gas analysis, comprehensive improvement score, and bacterial
culture of sputum were examined at 3, 6, 12 months, and at 2, 3, 4 years after the
initiation of the therapy. Pulmonary function improved in most of the patients within
6 months: the forced expiratory volume in one second showed a maximal increase
from a mean (SE) value of 1.74 (0.12) l at baseline to 2.31 (0.22) l at 6 months
(Po0:01) and the volume (l) of forced vital capacity also showed a maximal increase
within 6 months. The partial pressure of arterial oxygen at rest significantly increased
at 3–6 months. The comprehensive improvement score also reached maximum within
6 months in nine of the patients. The majority of patients have developed sputum
culture in which bacteria were negative within 6 months after the therapy. All of the
patients maintained a stable condition with continued therapy, and no side effects of
clarithromycin were observed during the study. This prospective study demonstrated
that 6-month treatment with clarithromycin might be necessary to improve the
clinical conditions of patients with DPB and the drug could be safely used for a long
term.
r 2003 Elsevier Science Ltd. All rights reserved.
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Introduction
Diffuse panbronchiolitis (DPB) is a chronic inflam-
matory airway disease that was first described in
1969 by Yamanaka et al.1 as a new clinicopathologic
entity. Though the disease is restricted almost
exclusively to Asian countries such as Japan, China,
Taiwan, and Korea,2 several cases have been
reported in non-Asian individuals.3–9
The etiology of DPB is not yet clear, and the
natural history of the disease is respiratory failure
leading to cor pulmonale and ultimately death.
Hemophilus influenzae and Streptococcus pneumo-
niae are often isolated from the sputum repeatedly
or continuously over a long period early in the
course of the disease and these bacteria are
replaced by Pseudomonas aeruginosa in most cases
when the disease reaches its advanced stage. The
chronic P. aeruginosa infection is caused by mucoid
strains of these bacteria growing as a biofilm which
is virtually impossible to eradicate by antibiotics.10
During this time, the respiratory bronchioles
become obstructed and the nearby airway bronch-
ioles become dilated. These changes are quite
similar to those of cystic fibrosis seen primarily in
Western countries.11
The prognosis of this disease was poor before
1985 in spite of numerous treatment alternatives
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with several antibiotics, corticosteroids, and life-
saving supportive therapy. According to the Re-
search Project Team of the Japanese Ministry of
Health and Welfare, the 10-year survival rate of
DPB cases in 1987 was 12.4% for cases infected with
P. aeruginosa and 73.1% for cases without P.
aeruginosa infection. After 1985, treatment was
modified to long-term erythromycin therapy at a
daily dose of 400–600mg, based on the first report
of an open trial showing the beneficial effects of
‘‘low-dose, long-term’’ treatment with erythromy-
cin (400–600mg/day for more than 6 months) in
DPB.12 This effect was later confirmed by a
placebo-controlled, double blind clinical trial.13
Other studies have also shown that erythromycin is
more effective than a new quinolone antibacterial
agent administered for 3 months,14 and ampicillin
administered for 3 months.15 Treatment using this
regimen has resulted in a significant improvement
in the survival rate of patients with DPB since 1985.
For example, the 10-year survival rate has in-
creased to more than 90%, marking a dramatic
improvement over the rates reported between
1970 and 1984.16 Subsequent to the above clinical
trial studies, we reported that oral administration
of roxithromycin (150mg/day) for more than 1
month also produced good results, such as improve-
ments in FEV1 and FVC to levels comparable to
those obtained with erythromycin. Our results also
showed no significant difference in the comprehen-
sive improvement score between patients treated
with roxithromycin and those treated with erythro-
mycin.17 Other macrolide antibiotics, clarithromy-
cin18 and azithromycin,19 have also been reported
to be equally effective in DPB.
However, since those studies were retrospective
with short courses of therapy (approximately 1–24
months) and a variety of assessment periods, it has
remained unclear when the efficacy of these drugs
appears and whether the drugs can be used safely
for a long term. Our group, therefore, conducted a
prospective open trial of long-term treatment with
the macrolide antibiotic. Clarithromycin instead of
erythromycin was employed in this study because
of the lower adverse effect on the gastrointestinal
tract.20
Methods
Patients
DPB was diagnosed using the following clinical
criteria established by the Ministry of Health and
Welfare of Japan in 1995. (1) Symptoms: all of
chronic cough, sputum, and dyspnea on exertion.
(2) Physical signs: coarse crackles, rhonchi, or
wheezes on auscultation of the chest. (3) Chest
radiographic findings: chest roentgenogram reveals
bilateral fine nodular shadows mainly in the lower
lung fields, and all patients received chest com-
puted tomograms in which the findings showing
small rounded areas of high attenuation with a
centrilobular distribution, branching linear areas of
high attenuation, and hypoattenuation in the
peripheral lung are more helpful in the diagnosis.21
(4) Pulmonary function tests and blood gas analysis:
FEV1% o70% and PaO2o 80mmHg. (5) Elevated
titers of cold hemagglutinin,  64 or higher. (6)
Past history or coexistence of chronic parasinusitis.
Such clinical findings can be used in making the
diagnosis of DPB. Histological studies, when possi-
ble, can confirm the diagnosis. The histological
features of DPB are characteristics and include
accumulation of lymphocytes and plasma cells
localized predominantly in the respiratory bronch-
ioles and adjacent centrilobular regions, and
accumulation of foamy macrophages in the wall
of respiratory bronchioles, adjacent alveolar ducts,
and alveoli with infiltration of lymphoid cells. If
patients were diagnosed only using the clinical
criteria, patients with a history of exposure to
organic or inorganic dust or drugs known to cause
bronchiolitis and those with connective tissue
disease or other chronic lung diseases causing
bronchiolitis were excluded and other obstructive
pulmonary diseases such as chronic bronchitis,
bronchial asthma, chronic emphysema and cystic
fibrosis were carefully ruled out. The study was
conducted between March 1995 and April 2000 in
Nagasaki University Hospital. The protocol was
approved by the ethics committee of Nagasaki
University Hospital, and all the patients provided
written informed consent.
Study design
Once diagnosed, the patients were treated with
200mg of clarithromycin per day for 4 years. If
patients had signs or roentgenographic findings
suggesting pneumonia or acute exacerbation of the
disease before enrollment in the study, adequate
antibiotics were administered. Thus, none had an
acute pulmonary infection in the 1 month before
enrollment in the study. The patients were in-
structed at each outpatients attendance to take
one tablet of clarithromycin (200mg) every 24 h, at
home, and were given a 4-week supply. They were
instructed to bring back any remaining tablets
at each visit so that the numbers of remaining
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tablets could be checked. Patients did not use any
other treatment for their disease during the entire
duration of the study, except for a short-term
antibiotic use when patients had acute exacerba-
tion of the disease.
Clinical and laboratory assessments, sputum
culture, pulmonary function tests, arterial blood
gas analysis at rest, and chest X-ray and CT scan
were performed at baseline, at 3, 6, and 12
months, and at 2, 3, and 4 years after initiating
the treatment. To evaluate the clinical efficacy of
clarithromycin treatment at each time point, we
also applied the comprehensive improvement
score13,14 assessed by the total score of five items,
namely chest radiographic abnormalities including
CT findings, FEV1, PaO2, the Hugh-Jones score, and
C-reactive protein (improvement¼ þ 1, no
change¼ 0, and worse¼1).
Patients were monitored for the occurrence of all
adverse events. Laboratory assessments were made
at each time point during the entire study period
and included complete blood count, chemistries,
and urinalysis. Clinically significant laboratory
abnormalities that could not be attributed to other
medical conditions were reported as adverse
events.
Statistical analysis
All values were expressed as mean (SE), and were
compared using one-factor ANOVA with Tukey–
Kramer post hoc analysis by the StatView 5.0
statistical package. A P-value of o0.05 was
considered significant.
Results
Patients
We enrolled ten patients (four men and six women,
mean age 50.3 (4.4) years, all non-smokers). The
clinical characteristics of the patients were sum-
marized in Table 1. Four of the patients were
pathologically diagnosed by surgical lung biopsy,
and the remaining were based on the clinical
criteria (all of six items were fulfilled in four of
the patients and five of the six items in the other
two patients). All patients completed the study.
Efficacy
Serial analysis of pulmonary function tests after
clarithromycin treatment is shown in Fig. 1. The
forced expiratory volume in 1 s started to rise from
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a mean of 1.74 (0.12) l at baseline to 2.21 (0.19) l at
3 months (Po0:01), and reached to a maximal
value with 2.31 (0.22) l (Po0:01; compared to that
at baseline) at 6 months and thereafter sustained
the same value until 4 years (Fig. 1a). The
significant increase in FEV1% also started after 6
months of treatment (Po0:05), and kept the same
value over the next follow-up periods (Fig. 1b). The
V25/Height (HT) also increased to a peak value of
0.45 (0.07) l/s/m from 0.28 (0.06) l/s/m at baseline
after 6 months of treatment, although not statis-
tically significant. The volume (l) of forced vital
capacity also rose to a maximal value within 6
months [3.16 (0.26) vs 2.57 (0.15) at baseline;
Po0:005], comparable with the value at each time
point (Fig. 1c). Although the forced vital capacity
was not deteriorated at baseline, it also increased
significantly from a mean of 88.2 (5.3)% of the
predicted value at baseline to 103.6 (3.9)% after 3
months of treatment (Po0:001), and no differences
were observed between each time point (Fig. 1d).
The partial pressure of arterial oxygen at rest
significantly increased to 85.0 (2.6)mmHg at 3
years compared with that at baseline, and this
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Figure 1 Serial analysis of pulmonary function tests after clarithromycin treatment. Pulmonary function tests and
arterial blood gas analysis were performed at 3, 6, and 12 months, and at 2, 3, and 4 years after initiating the
treatment. *Po0:01; **Po0:05; #Po0:001; ##Po0:005 compared to the values at baseline, and $Po0:05 compared to
the values at 3 and 6 months.
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value were significantly higher than that at 3 or 6
months (Po0:05). However there were no signifi-
cant differences in the values between 3 or 6
months and 4 years (Fig. 1e). The comprehensive
improvement score reached maximum at 3 months
in seven, 6 months in two and 2 years in one of the
patients with an excellent improvement in eight, a
moderate improvement in one and a mild improve-
ment in one, and thereafter kept their stable
condition (Table 2). The latter patient (patients No.
10) showed only minimal response to therapy
because she had normal lung function and low
CHA titer at baseline which could not be markers of
significance.
The organisms identified on sputum culture
throughout the 4-year period of clarithromycin
therapy are shown in Table 3. Sputum cultures
were performed at least 3 times during each
treatment period in the following 2, 3, 4 years.
Sputum sample isolated from the patients at each
time point was from their stable condition except
for case 6 in which acute exacerbation occurred at
6 months after the therapy. Five of the patients
demonstrated no bacterial growth in their sputum
and sputum in two of the patients disappeared
within 6 months. Sputum in another three of the
patients also disappeared throughout the study
period (two and one of the patients at 12 months
and 2 years, respectively). The remaining patients
(patient No. 2, 6, 8, 9, 10) still had sputum
but decreased even with positive bacterial
culture (Klebsiella pneumoniae: 4 104 cfu/ml,
ARTICLE IN PRESS
Table 2 Comprehensive improvement score after clarithromycin treatment.
Case No. 3 months 6 months 12 months 2 years 3 years 4 years
1 þ 5 þ 5 þ 5 þ 5 þ 5 þ 4
2 þ 4 þ 4 þ 4 þ 4 þ 4 þ 3
3 þ 3 þ 4 þ 4 þ 4 þ 4 þ 3
4 þ 3 þ 4 þ 4 þ 5 þ 4 þ 3
5 þ 3 þ 3 þ 2 þ 2 þ 2 þ 1
6 þ 4 þ 4 þ 2 þ 2 þ 4 þ 3
7 þ 5 þ 5 þ 5 þ 5 þ 4 þ 2
8 þ 5 þ 5 þ 5 þ 5 þ 5 þ 4
9 þ 1 þ 4 þ 4 þ 4 þ 4 þ 3
10 þ 1 þ 1 þ 1 þ 1 0 0
þ 4 to þ 5: excellent improvement, þ 2 to þ 3: moderate improvement, þ 1: mild improvement, 0: no change.
Table 3 Bacteria isolated from sputum of the patients after clarithromycin treatment.
Case No. before 3 months 6 months 12 months 2 years 3 years 4 years
1 HPh (0.02)a SP (1) SM (0.01) F F F F
HPi (0.6)
2 HI (0.4) HPi (0.2) NF NF NF NF NF
3 HI (0.005) NF NF F F F F
4 SP (10) NF PA (6) PA (10) F F F
PF (0.1)
5 NF NF (F)b F F F F
6 NF MC (20) HI (20) PRSP (4), HPh (0.04) PRSP (1) SP (2), SA (0.01) SA (0.04)
HI (10) HI (8) HI (10) HI (4)
7 PA (10) SA (0.2) F F F F F
BB (6)
8 NF NF NF HPh (0.2) KP (3) NF KP (0.004)
9 SP (6) PA (10) NF NF PA (5) NF NF
10 NF NF NF NF NF NF AF (0.05)
HPh: Hemophilus parahaemolytics, HI: Hemophilus influenzae, SP: Streptococcus pneumoniae, PA: Pseudomonas aeruginosa,
MC: Moraxella catarrhalis, HPi: Hemophilus parainfluenzae, SA: Staphylococcus aureus, BB: Bordetella bronchiseptica, SM:
Serratia marcescens, PF: Pseudomonas fluorescens, PRSP: penicillin-resistant Streptococcus pneumoniae, KP: Klebsiella
pneumoniae, AF: Alcaligenes faecalis, NF: normal flora.
aNumber of isolated bacteria;  107 cfu/ml.
bNo sputum.
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Alcaligenes faecalis: 5 105 cfu/ml, Staphylococ-
cus aureus: 4 105 cfu/ml, and normal flora) at the
last time point. S. pneumoniae strains resistant to
penicillin G (MIC: 1.0 mg/ml) and resistant to both
penicillin G (MIC: 4.0 mg/ml) and erythromycin
(MIC: 4.0 mg/ml) were isolated in sputum obtained
from one of the remaining patients (patient No. 6)
at 12 months and 2 years after the therapy,
respectively. However, the bacteria were replaced
by S. aureus during the next follow-up periods.
None of the patients had been hospitalized with
serious pulmonary infection including acute ex-
acerbation caused by the bacteria isolated from
sputum during the course of the study.
Adverse events
There were no adverse effects in the physical and
laboratory findings except for one patient who had
transient mild diarrhea for a few days after
initiating the treatment (case 7).
Discussion
During this decade, DPB became a curable disease
with low-dose and long-term erythromycin treat-
ment.16 Other 14-membered macrolides such as
clarithromycin and roxithromycin or 15-membered
macrolide, azithromycin also have a good effi-
cacy.17–19 However, since those studies were retro-
spective with a short course of the therapy for
approximately 1–24 months and a variety of
assessment period, it was unclear when the efficacy
of the drugs appears and whether the drugs can be
used safely for a long term. In a prospective study,
a significant improvement was initially found in
FEV1, VC, %VC and PaO2 at 3 months but in FEV1% at
6 months after the therapy, and most of the
patients had a significant maximal improvement
in pulmonary ventilation at 6 months although the
value between 3 and 6 months was not statistically
different. Gas exchange had a maximal improve-
ment at 3 years with a significantly higher value
than that at 3 or 6 months, and no significant
differences were observed in the values between 3
or 6 months and 4 years after the therapy. In
addition, the comprehensive improvement score
reached maximum within 6 months, and the
bacteriologic data demonstrated that the majority
of patients have certainly developed sputum
culture in which bacteria became negative by 6
months of therapy. This study also showed that the
improvement observed at 6 months was stable over
the next follow-up period until 4 years with
continued therapy. These results indicate that 6-
month treatment with clarithromycin might be
necessary to improve the clinical condition of
patients with DPB. This effect of the drug was also
observed in the presence of bacteria (irrespective
of bacterial eradication), and it is emphasized that
the two patients with P. aeruginosa in the sputum
and marked impairment of lung function responded
well to therapy since such patients have been
reported to be the worse prognosis if untreated.2,16
This confirmed the previous findings that macro-
lides act as anti-inflammatory rather than bacter-
icidal agents.17,22,23 However, the present study
cannot answer the question of whether the stability
would continue if the antibiotic was stopped after 6
months, or in other words, of whether orally
administrated clarithromycin must last 4 years in
order to keep patients’ stable condition.
Long-term administration of the drug was well
tolerated by all study participants with no physical
problems, laboratory abnormalities, or other ser-
ious adverse events. Additionally, it has been
reported that clarithromycin-related side-effects
on the gastrointestinal tract may be significantly
less than those of erythromycin.20 These results
may indicate the advantages of clarithromycin
administration as compared with erythromycin.
However, there has been concern about the
development of S. pneumoniae resistant to macro-
lide, as multidrug-resistant S. pneumoniae, includ-
ing penicillin- and macrolide-resistant strains, have
become a serious public health problem in Japan
and many other countries as the rates of infection
from these bacteria continue to grow.24,25 In this
study, S. pneumoniae unsusceptible to macrolide
was only isolated in sputum from one of the ten
patients. Later in the course of the study it was
replaced by other bacteria, and there was no
pulmonary infection caused by resistant bacteria.
In conclusion, this study showed that 6-month
treatment with clarithromycin might be necessary
to improve the clinical condition of patients with
DPB and the drug could be used safely with no
prominent adverse effect during 4-year adminis-
tration. The present result gives an important
information to physicians in East Asia and even
western countries coping with DPB.
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